Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of birelentinib (DZD8586) versus investigator's choice in relapsed/refractory CLL/SLL
2025-522669-32-00Phase 3Authorised
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of birelentinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: authorised.
02
Drugs
birelentinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-522669-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522669-32-00.